PharmaMar leads the ONCOLIBERYX consortium together with four research centers to develop new marine-based oncology drug administration strategies

The project, given the necessity for public-private collaboration projects, approved by the Ministry of Science and Innovation, has a financing of €3.49 million from funds from the Recovery, Transformation and Resilience Plan.

ONCOLIBERYX project - PharmaMar
Acceso a la innovación
Innovative drugs

The ONCOLIBERYX project, led by PharmaMar (MSE:PHM), brings together four leading Spanish research groups in nanotechnology and oncology, to develop unique formulations that could lead to new oncology therapies based on the marine compounds in PharmaMar's collection.

The consortium relies on the experience and expertise of renowned Spanish researchers in the field of new drug delivery systems, immunotherapy and cancer, such as Professors María José Alonso (University of Santiago de Compostela), María Blanco (University of Navarra), Ignacio Melero (Cima University of Navarra) and José Luis Pedraz (University of the Basque Country).

Today, cancer is the second leading cause of death in developed Western countries. Despite remarkable advances in the elucidation of the biological mechanisms underlying this disease and new therapeutic approaches, concerns about the side effects caused by these drugs are driving research into more selective and effective therapeutic regimens and formulations.

ONCOLIBERYX focuses on the search for new drug delivery strategies, in order to increase the specificity of oncological active compounds, decreasing their toxicity and side effects, while maintaining and/or increasing their therapeutic effects.

Pilar Calvo, Ph.D., Head of Analytical and Pharmaceutical Development at PharmaMar and technical coordinator of the project, emphasizes that “in the last 20 years, drug nanocarriers - liposomes, lipid and polymeric nanoparticles, micelles, antibody-drug conjugates, etc. - have demonstrated notable advantages in meeting these challenges. The research resulting from PharmaMar's collaboration with these innovative research groups will undoubtedly lead to progress in the search for more effective and safer drugs”.

Attached files
PR_PhM_ONCOLIBERYX_0.pdf424.32 KBDownload